Treatment

Kamada-AAT for Inhalation clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective Phase III Multi-center, 2-Year Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of “Kamada-AAT for Inhalation” 80 mg per Day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), Followed by a 2-Year Open- Label Extension
This study looks at a new inhaled medicine, Kamada-AAT, for adults with a genetic lung condition called Alpha-1 antitrypsin deficiency. Researchers want to see if it improves breathing and overall lung health over two years compared to a dummy treatment, followed by two years where everyone gets the medicine.
For: Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted · FEV1/SVC ≤ 70%) · and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.
Finland · Ireland · Sweden